U.S. market Open. Closes in 3 hours 1 minute

APLS | Apellis Pharmaceuticals, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Revenue396.59M75.42M66.56M250.65MN/AN/AN/AN/AN/AN/AN/A
Cost of Revenue60.21M5.64M5.20M25.05M288.02M127.92MN/AN/AN/AN/AN/A
Gross Profit336.38M69.79M61.36M225.60M-288.02M-127.92MN/AN/AN/AN/AN/A
Operating Expenses853.50M664.40M597.64M439.32M288.02M127.92M50.77MN/AN/AN/AN/A
Selling, General & Admin499.11M277.16M176.77M139.40M67.05M22.64M10.46M4.30M6.36M2.91M1.71M
Research & Development354.39M387.24M420.87M299.92M220.97M105.29M40.30M22.98M13.73M8.38M2.32M
Other Operating Expenses-727.00K-288.00K1.36M-501.00K-175.31K-110.76KN/A-27.28M-20.09M-11.29M-4.02M
Operating Income-517.12M-594.61M-536.28M-213.73M-288.02M-127.92M-50.77M-27.28M-20.09M-11.29M-4.03M
Other Expenses / Income-9.38M-56.89M-209.72M-129.30M-16.69M-25.25K-239.06K157.71K-26.43M62.46K68.00K
Before Tax Income-526.50M-651.50M-746.00M-343.03M-304.71M-127.50M-51.01M-27.12M-46.52M-11.23M-3.96M
Income Tax Expenses2.13M669.00K352.00K1.84M5.11M-533.32KN/AN/AN/A-443.34KN/A
Net Income-528.63M-652.17M-746.35M-344.87M-309.82M-127.50M-51.01M-27.12M-46.52M-10.79M-3.96M
Interest Expenses29.58M32.63M13.24M29.94M5.28M2.51MN/AN/AN/AN/AN/A
Basic Shares Outstanding118.68M106.11M84.42M75.16M62.23M54.40M13.87M18.01M18.09M18.09M18.09M
Diluted Shares Outstanding118.68M106.11M84.42M75.16M62.23M54.40M13.87M18.01M18.09M18.09M18.09M
EBITDA-515.42M-584.50M-533.00M-209.43M-282.84M-125.07M-50.99M-27.28M6.40M-11.29M-4.02M
EBITDA Margin-129.96%-774.97%-800.75%-83.55%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
EBIT-496.92M-618.88M-732.76M-313.09M-299.42M-125.52M-51.01M-27.12M-46.52M-11.23M-3.96M
EBIT Margin-125.30%-820.55%-1,100.85%-124.91%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙